Journals / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2006 / Cilt: 14 - Sayı: 2

Kolesterol ester proteini ve reoperatif koroner arter cerrahisi

Cholestryl ester transfer protein and reoperative coronary artery surgery

Pages
101–106
Publication Date
2022-09-02
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Screening younger patients for CETP activity may predict middle and long term prognosis and the use of "athero-resistant" grafts (e.g. arterial grafts) may be particularly important in those patients with a CETP activity above the cut-off point of 9.34.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: The activity of cholesteryl ester transfer protein (CETP) has been assessed in patients with occluded grafts following coronary artery bypass grafting (CABG).
📊
Key Findings & Data:Methods: Twenty patients undergoing re-operative CABG (group 1) between June, 2003 and November, 2004 were prospectively compared with control groups (20 patients undergoing primary, isolated CABG -group 2 and 20 patients undergoing isolated non-ischemic valvular procedures- group 3) for CETP activity, pre-, peri- and postoperative data including hospital mortality and mortality.
💡
Conclusion & Impact:Conclusion: Screening younger patients for CETP activity may predict middle and long term prognosis and the use of "athero-resistant" grafts (e.g. arterial grafts) may be particularly important in those patients with a CETP activity above the cut-off point of 9.34.
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Abstract

Background: The activity of cholesteryl ester transfer protein (CETP) has been assessed in patients with occluded grafts following coronary artery bypass grafting (CABG). Methods: Twenty patients undergoing re-operative CABG (group 1) between June, 2003 and November, 2004 were prospectively compared with control groups (20 patients undergoing primary, isolated CABG -group 2 and 20 patients undergoing isolated non-ischemic valvular procedures- group 3) for CETP activity, pre-, peri- and postoperative data including hospital mortality and mortality. For statistical reason, groups 2 and 3 were denominated as 'group B' which delineates progressive atherosclerosis in some evaluations. Results: Cholesteryl ester transfer protein activity was highest in group 1 (14.28±3.87; 5.42±3.59; 7.08±3.87 in groups 1-3, respectively; p<0.05). 50% of patients in group 1 had a three-graft CABG (2.85±0.99 grafts/patient). One patient expired in group 1; two of three cases of perioperative myocardial infarction were from group 1. Cholesteryl ester transfer protein activity higher than 9.34 was recognized as the limit of progressive atherosclerosis. Area under the receiver operator characteristic curve (ROC) was 0.085 indicating that the analysis was very good. Conclusion: Screening younger patients for CETP activity may predict middle and long term prognosis and the use of "athero-resistant" grafts (e.g. arterial grafts) may be particularly important in those patients with a CETP activity above the cut-off point of 9.34.

Özet

Amaç: Koroner arter bypass cerrahisi sonrası greftleri tıkanmış olan hastalarda, kolesterol ester transfer proteininin (KETP) aktivitesi değerlendirildi. Çalışma planı: Haziran 2003 Kasım 2004 tarihleri arasında koroner arter bypass tekrar cerrahisi geçiren 20 hasta (grup 1) ile kontrol grupları (primer koroner bypass cerrahisi geçiren 20 hasta [grup 2] ve iskemik nedenlere bağlı olmayan kalp kapak ameliyatı geçiren 20 hasta [grup 3]) KETP aktivitesi, hastaların özellikleri ve hastane mortalite/ morbiditesi açısından karşılaştırıldı. İstatistiksel inceleme açısından grup 2 ve 3 bazı değerlendirmelerde progresif aterosklerozu gösterdiği öngörülen "grup B" olarak adlandırıldı. Bulgular: En yüksek KETP aktivitesi grup 1'de bulundu (sırasıyla 14.28±3.87; 5.42±3.59; 7.08±3.87- grup 1'le karşılaştırıldığında p<0.05). Grup 1 hastalarının yarısında daha önce üç greft kullanıldığı belirlendi (2.85±0.99 greft/hasta). Kaybedilen tek hasta ve belirlenen üç peroperatif miyokard infarktüsü olgusundan ikisi grup 1'de idi. Kolesterol ester transfer proteinin aktivitesi açısından 9.34 değeri progresif aterosklerozun başladığı sınır olarak belirlendi. Kullanılan ROC (receiver operating characteristic curve) analizinde eğri altında kalan alan 0.085- çok iyi olarak bulundu. Sonuç: Genç hastalarda KETP aktivitesinin taranması, bu hastaların orta ve uzun dönem prognozu hakkında bilgi verebilir ve özellikle KETP aktivitesi sınırın üzerindeki hastalarda "aterorezistan" (örn. arteryel) greftlerin tercihi önem kazanmaktadır.

🔖

Cite This Article

FİLİZCAN, U., ÇINAR, B., EREN, E., ÇETEMEN, Ş., GÖKSEL, O., ŞAHİN, V., BAYSERKE, O., KUT, S. (2022). Kolesterol ester proteini ve reoperatif koroner arter cerrahisi. Türk Göğüs Kalp Damar Cerrahisi Dergisi, Cilt: 14 - Sayı: 2, 101–106. https://ajindex.com/articles/425210

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-7
  2. Sugano M, Sawada S, Tsuchida K, Makino N, Kamada M. Low density lipoproteins develop resistance to oxidative modification due to inhibition of cholesteryl ester transfer protein by a monoclonal antibody. J Lipid Res 2000;41:126-33
  3. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255-74
  4. Agerholm-Larseri B, Tybjaerg-Hansen A, Schnohr P, Steffensen R, Nordestgaard BG. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study. Circulation 2000; 102:2197-203
  5. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AV, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338:86-93
  6. Koizumi J, Mabuchi H, Yoshimura A, Michishita I, Takeda M, Itoh H, et al. Deficiency of serum cholesteryl-'ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis 1985;58:175 86
  7. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990;323:1234-8
  8. Koizumi J, Inazu A, Yagi K, Koizumi I, Uno Y, Kajinami K, et al. Serum lipoprotein lipid concentration and composition in homozygous and heterozygous patients with cholesteryl ester transfer protein deficiency. Atherosclerosis 1991; 90:189-96
  9. Hill SA, Thomson C, McQueen MJ. Cholesteryl ester transfer protein mutations, protein activity and HDL-cholesterol concentration. Clin Chem Lab Med 1998;36:629-32. 10. van Brussel BL, Plokker HW, Ernst SM, Ernst NM, Knaepen PJ, Koomen EM, et al. Venous coronary artery bypass surgery. A 15-year follow-up study. Circulation 1993;88(5 Pt 2):II87-92
  10. Lytle BW, Loop FD, Taylor PC, Goormastic M, Stewart RW, Novoa R, et al. The effect of coronary reoperation on the survival of patients with stenoses in saphenous vein bypass grafts to coronary arteries. J Thorac Cardiovasc Surg 1993; 105:605-12
  11. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al. Effect of coronary artery bypass graft surgery on survival: overv